Read the full stored bill text
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
83rd OREGON LEGISLATIVE ASSEMBLY--2025 Regular Session
A-Engrossed
House Bill 3817
Ordered by the House April 16
Including House Amendments dated April 16
Sponsored by Representative SKARLATOS, Senator SMITH DB; Representatives CHOTZEN, HARBICK, LEWIS,
LIVELY, RESCHKE, Senators STARR, THATCHER
SUMMARY
The following summary is not prepared by the sponsors of the measure and is not a part of the body thereof subject
to consideration by the Legislative Assembly. It is an editor’s brief statement of the essential features of the
measure. The statement includes a measure digest written in compliance with applicable readability standards.
Digest: The Act tells OHA and DVA to study the use of ibogaine by some people to help
treat certain disorders. (Flesch Readability Score: 68.0).
[Digest: The Act tells OHA and DVA to set up a process to let a person with a certain disorder
use ibogaine to help treat the disorder. (Flesch Readability Score: 63.3). ]
Directs the Oregon Health Authority [ in collaboration with ] and the Department of Veterans’
Affairs to [ establish a process through which a certain individual may consume ibogaine for a specified
purpose] study the consumption of ibogaine by certain individuals for the purpose of treating
specified disorders . Defines “ibogaine.” Requires the authority and the department to submit a
report to the interim committees of the Legislative Assembly related to health care [ and veterans ]
not later than September 15, 2029. [ Exempts ibogaine, when obtained and consumed through the es-
tablished process, from the definition of “controlled substance.” ]
Sunsets on January 2, 2030.
A BILL FOR AN ACT
Relating to ibogaine.
Be It Enacted by the People of the State of Oregon:
SECTION 1.
(1) As used in this section, “ibogaine” means a naturally occurring indole
alkaloid extracted from the root bark of the Tabernanthe iboga shrub.
(2) The Oregon Health Authority and the Department of Veterans’ Affairs shall study the
consumption of ibogaine by individuals who have post-traumatic stress disorder, major
depressive disorder, an anxiety disorder or substance use disorder for the purpose of treating
the disorder. The authority and the department shall submit a report in the manner provided
by ORS 192.245, and may include recommendations for legislation, to the interim committees
of the Legislative Assembly related to health care no later than September 15, 2029. The re-
port must include information about and recommendations on the following:
(a) The available medical, psychological and scientific studies, research and other data
relating to the safety and efficacy of ibogaine;
(b) The sourcing and production of ibogaine;
(c) Recommended doses and delivery methods of ibogaine;
(d) Testing and safety of ibogaine products;
(e) Best practices for client and public health and safety, including client data protection
and client consent;
(f) Training and requirements for individuals who administer ibogaine to clients;
(g) Requirements for how ibogaine is administered to clients and how clients are prepared
and supported through the duration of and after administration;
NOTE:Matter in boldfaced type in an amended section is new; matter [ italic and bracketed] is existing law to be omitted.
New sections are in boldfaced type.
LC 4313
A-Eng. HB 3817
1
2
3
4
5
6
7
8
9
(h) Requirements for a system to track ibogaine and locations at which ibogaine will be
produced, stored and administered or consumed;
(i) Client screening and eligibility requirements for consumption of ibogaine, and any
conditions that would cause a client to be ineligible;
(j) Funding mechanisms for the administration of an ibogaine program and the long-term
sustainability of the program; and
(k) Reporting of data on ibogaine consumption and client outcomes.
SECTION 2.
Section 1 of this 2025 Act is repealed on January 2, 2030.
[2]